X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ALEMBIC LTD - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ALEMBIC LTD NOVARTIS/
ALEMBIC LTD
 
P/E (TTM) x 421.2 54.3 775.2% View Chart
P/BV x 29.7 2.2 1,366.3% View Chart
Dividend Yield % 1.5 0.5 328.1%  

Financials

 NOVARTIS   ALEMBIC LTD
EQUITY SHARE DATA
    NOVARTIS
Mar-18
ALEMBIC LTD
Mar-18
NOVARTIS/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs75872 1,052.8%   
Low Rs57934 1,708.0%   
Sales per share (Unadj.) Rs228.44.7 4,858.6%  
Earnings per share (Unadj.) Rs31.76.1 520.0%  
Cash flow per share (Unadj.) Rs32.86.2 524.6%  
Dividends per share (Unadj.) Rs10.000.20 5,000.0%  
Dividend yield (eoy) %1.50.4 396.0%  
Book value per share (Unadj.) Rs297.140.7 730.8%  
Shares outstanding (eoy) m24.69267.03 9.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.911.3 26.0%   
Avg P/E ratio x21.18.7 242.8%  
P/CF ratio (eoy) x20.48.5 240.7%  
Price / Book Value ratio x2.21.3 172.8%  
Dividend payout %31.53.3 961.6%   
Avg Mkt Cap Rs m16,50514,139 116.7%   
No. of employees `0000.7NA-   
Total wages/salary Rs m1,445207 696.9%   
Avg. sales/employee Rs Th8,441.3NM-  
Avg. wages/employee Rs Th2,163.6NM-  
Avg. net profit/employee Rs Th1,173.1NM-  
INCOME DATA
Net Sales Rs m5,6391,255 449.2%  
Other income Rs m1,718370 464.2%   
Total revenues Rs m7,3571,625 452.6%   
Gross profit Rs m-63111 -56.3%  
Depreciation Rs m2538 66.9%   
Interest Rs m552 3,252.9%   
Profit before tax Rs m1,575442 356.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m79224 3,305.2%   
Profit after tax Rs m7841,630 48.1%  
Gross profit margin %-1.18.9 -12.5%  
Effective tax rate %50.35.4 927.0%   
Net profit margin %13.9129.8 10.7%  
BALANCE SHEET DATA
Current assets Rs m9,5221,867 510.0%   
Current liabilities Rs m3,296591 557.5%   
Net working cap to sales %110.4101.6 108.6%  
Current ratio x2.93.2 91.5%  
Inventory Days Days3794 38.8%  
Debtors Days Days2874 38.6%  
Net fixed assets Rs m461,791 2.6%   
Share capital Rs m123534 23.1%   
"Free" reserves Rs m7,21310,324 69.9%   
Net worth Rs m7,33610,858 67.6%   
Long term debt Rs m041 0.0%   
Total assets Rs m11,10511,591 95.8%  
Interest coverage x29.5260.9 11.3%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.1 468.9%   
Return on assets %7.614.1 53.7%  
Return on equity %10.715.0 71.2%  
Return on capital %22.215.2 146.3%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m6119 312.4%   
Fx outflow Rs m3,630264 1,376.0%   
Net fx Rs m-3,570-244 1,460.4%   
CASH FLOW
From Operations Rs m1,610236 682.7%  
From Investments Rs m687-224 -306.7%  
From Financial Activity Rs m-2,677-27 10,062.0%  
Net Cashflow Rs m-380-15 2,564.9%  

Share Holding

Indian Promoters % 0.0 64.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 0.2 1,000.0%  
FIIs % 1.6 9.7 16.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 26.1 82.4%  
Shareholders   41,647 54,701 76.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  UNICHEM LAB  WYETH LTD  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Energy and Automobiles Stocks Drag(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.9% while the Hang Seng is up 0.2%.

Related Views on News

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ALEMBIC LTD Announces Quarterly Results (3QFY19); Net Profit Down 41.9% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, ALEMBIC LTD has posted a net profit of Rs 32 m (down 41.9% YoY). Sales on the other hand came in at Rs 243 m (down 18.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 23, 2019 10:05 AM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS